MLL2/KMT2B (E6A8V) Rabbit Monoclonal Antibody (Carboxy-terminal Antigen) #38058
- WB
- IP
Product Specifications
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 80 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
MLL2, also known as histone-lysine N-methyltransferase 2B (KMT2B), functions to activate gene expression by mediating tri-methylation of histone H3 lysine 4 at the promoters of genes involved in embryogenesis and hematopoiesis, and is required for histone H3 lysine 4 tri-methylation at bivalent promoters in embryonic stem cells (7). Like MLL1, MLL2 is a large protein made up of approximately 2,700 amino acids that is cleaved by the Taspase 1 threonine endopeptidase to form N-terminal (MLL2-N) and C-terminal (MLL2-C) fragments, both of which are subunits of the functional MLL2/COMPASS complex. MLL2-N, MLL2-C, WDR5, RBBP5, and ASH2L define the core catalytic component of the MLL2/COMPASS complex, which is recruited to target genes to regulate transcription. MLL1 gene translocations are often associated with various hematological malignancies and thought to be a driving component of these types of leukemia. MLL2 is required for memory formation, proper glucose homeostasis, and cardiac lineage differentiation of mouse embryonic stem cells (8-11). A recent study has shown that MLL2 is required for survival of MLL-AF9-transformed cells, implicating MLL2 as a potential modulator of MLL1-rearranged leukemias (12). Mutations in MLL2 cause complex early-onset dystonia, and overexpression of MLL2 is associated with gastrointestinal diffuse large B-cell lymphoma (13,14).
- Miller, T. et al. (2001) Proc Natl Acad Sci U S A 98, 12902-7.
- Shilatifard, A. (2008) Curr Opin Cell Biol 20, 341-8.
- Tenney, K. and Shilatifard, A. (2005) J Cell Biochem 95, 429-36.
- Lee, J.H. and Skalnik, D.G. (2005) J Biol Chem 280, 41725-31.
- Lee, J.H. et al. (2007) J Biol Chem 282, 13419-28.
- Hughes, C.M. et al. (2004) Mol Cell 13, 587-97.
- Denissov, S. et al. (2014) Development 141, 526-37.
- Kerimoglu, C. et al. (2017) Cell Rep 20, 538-48.
- Kerimoglu, C. et al. (2013) J Neurosci 33, 3452-64.
- Goldsworthy, M. et al. (2013) PLoS One 8, e61870.
- Wan, X. et al. (2014) Stem Cell Rev 10, 643-52.
- Chen, Y. et al. (2017) Cancer Cell 31, 755-770.e6.
- Meyer, E. et al. (2017) Nat Genet 49, 223-37.
- Ye, H. et al. (2015) Int J Clin Exp Pathol 8, 13043-50.
Alternate Names
CXXC10; DYT28; Histone-lysine N-methyltransferase 2B; Histone-lysine N-methyltransferase MLL4; HRX2; KIAA0304; KMT2B; KMT2D; lysine (K)-specific methyltransferase 2B; lysine methyltransferase 2B; Lysine N-methyltransferase 2B; Lysine N-methyltransferase 2D; mixed lineage leukemia gene homolog 2; MLL1B; MLL2; MLL4; myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila) 4; myeloid/lymphoid or mixed-lineage leukemia 4; Myeloid/lymphoid or mixed-lineage leukemia protein 4; Trithorax homolog 2; trithorax homologue 2; TRX2; WBP-7; WBP7; WW domain binding protein 7; WW domain-binding protein 7
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专